A comparative trial of a controlled-release iron tablet preparation ('Ferrocontin' Continus) and ferrous fumarate tablets.

Abstract

A single-blind, crossover comparative study was carried out in 40 patients with iron deficiency anaemia to assess the clinical efficacy and tolerance of once daily treatment with a controlled-release preparation of ferrous glycine sulphate ('Ferrocontin' Continus) and ferrous fumarate. Patients were allocated at random to receive 1 tablet (equivalent to 100 mg elemental iron) daily of one or other preparation for 4 weeks and were then crossed over to the alternative preparation for a further 4 weeks. The results showed that the significant increases in haemoglobin, packed cell volume and mean corpuscular volume were similar with both preparations. Seventeen patients reported gastro-intestinal side-effects on one or both preparations and the incidence was slightly less in patients whilst receiving the ferrous glycine sulphate preparation. In 3 patients, side-effects were sufficiently severe whilst taking ferrous fumarate to warrant interruption of treatment in 2 and withdrawal from the study in the other.

• Authors: A Aronstam, D L Aston
• Journal: Pharmatherapeutica (Pharmatherapeutica) Vol. 3 Issue 4 Pg. 263-7 ( 1982) ISSN: 0308-051X [Print] England
• PMID: 7146040 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Delayed-Action Preparations
• Ferrous Compounds
• Hemoglobins
• Tablets
• Iron
• ferroglycine sulfate
• ferrous fumarate
• Glycine

Topics

• Adult
• Anemia, Hypochromic (blood, drug therapy)
• Blood Cell Count
• Delayed-Action Preparations
• Drug Evaluation
• Female
• Ferrous Compounds (administration & dosage, adverse effects)
• Glycine (administration & dosage, adverse effects, analogs & derivatives)
• Hemoglobins (metabolism)
• Humans
• Iron (administration & dosage, adverse effects, blood)
• Male
• Protein Binding
• Tablets